Newpubli (ISSN 2474-8242) is the first fifth-generation scientific journal

Newpubli provides a value rank for each article through peer review

About us


1. Introduction of Newpubli
Newpubli (ISSN 2474-8242) is an academic journal published by the non-profit Newpubli Corporation which is located in Chicago, the USA.
As the first fifth-generation academic journal, Newpubli inaugurated multiple brave and brilliant innovations.
The term “Newpubli” is abbreviated from “New Publication”.
Newpubli Corporation also publishes another academic journal, Newpubli Express (ISSN 2474-8250), which is subsidiary to Newpubli because Newpubli Express utilizes the website, editorial team and editorial system of Newpubli.
The words “we”, "our” and “us” in this page represent the Newpubli Corporation and/or the journals of Newpubli and Newpubli Express.
This page describes the mission, features, peer review mode and some editorial policies of Newpubli. For information about Newpubli Express, please see Newpubli Express.
Newpubli neither requires readers to pay any fees for reading articles, nor requires authors to pay any fees for open-access publication.
This page will be updated from time to time.


2. Mission of Newpubli
Newpubli undertakes the mission to change the traditional slow, stressful, expensive and prejudiced process for article publication into a rapid, pleasant, free and fair journey, through multiple brave and brilliant innovations.
Newpubli shall greatly minimize the burdens of authors and editors in academic publishing, greatly minimize the negative effect of prejudice on academic publishing, and greatly facilitate dissemination of novel research data.


3. Background of Newpubli
There are around 28,000 active academic journals in the world, collectively publishing about 1.8–1.9 million articles per year. These journals serve as the predominant vehicle for recording, introducing, sharing and disseminating new data, techniques, views and theories developed by researchers, and thus they are paramount in furthering scientific progress.
The around 28,000 academic journals can be classified into four generations in recent years. First-generation journals are costly printed in paper and accessible only to subscribers. Second-generation journals are also accessible only to subscribers, but they are electronic and so greatly cut the cost in journal production and distribution. Third-generation journals are electronic and open access which removed the great financial burden of readers and libraries in accessing published articles. Fourth-generation journals, such as PLOS One, Peerj and F1000Research, are electronic and open access. They may not reject articles only because of limited value, an dthey provide a series of post-publication metrics, such as the times an article have been viewed, downloaded and cited, to aid readers to judge the value of the article.
Despite the rapid development of academic journals in recent years, the inherent conflict between authors and journals, i.e., that authors are reluctant to publish their articles of high value in journals of low impact, and journals of high impact are reluctant to publish articles of low value, remains unchanged. This conflict has frustrated authors and journals for many years. It also makes peer review tough and prejudice highly prevalent in the first, second and third generations of academic journals, and makes authors reluctant to submit their articles to fourth-generation journals for publication which are usually of low or no impact factors.
To remove the inherent conflict between authors and journals is the main direct target of Newpubli which is the first fifth-generation academic journal.


4. Principle of Newpubli
Newpubli harbors nine sub-journals (similar to sections of a journal) which publish articles rated through solid peer review to be largely as valuable as the ones published in some journals whose impact factors are 0–0.5, 0.5–1.5, 1.5–2.5, 2.5–3.5, 3.5–4.5, 4.5–5.5, 5.5–10.5, 10.5–20.5 and ≥ 20.5, respectively. Consequently, authors of most articles need not worry about that their articles may be rejected or underestimated, and the inherent conflict between authors and journals shall be completely removed, because authors shall be willing to publish their articles of high value in Newpubli, as these articles shall be rapidly published with high PR-Ranks in some sub-journals of high impact, and articles of low value will not be rejected for publication as these articles can be published with low value ranks in some sub-journals of low impact.
Some other innovations, as detailed below, have also been integrated in Newpubli to aid to change the traditional slow, stressful, expensive and prejudiced process for article publication into a rapid, pleasant, free and fair journey.


5. Features of Newpubli
5.1 Wide scope: Newpubli shall publish articles from all disciplines, although Newpubli publishes only biomedical articles in the beginning years, and may reject to publish manuscripts on some special topics (e.g., politics, religions and eroticism) without explanation.
5.2 Open access: All articles published by Newpubli can be read, downloaded, saved, copied and printed by anyone without any restriction.

5.3 Copyright protection:The copyright of any article published by Newpubli belongs to its authors; authors can protect the copyright of their articles published by Newpubli in a rational way as long as their articles, preprints and news published by Newpubli are open access as defined above. For example, the corresponding author can require that any part of the relevant article cannot be used without citation for non-commercial use or without permission for commercial use. Additionally, all authors should allow the metadata of preprints and articles related to indexing, searching and citation should be used without any restriction.

5.4 Multiple stages of publication:Publication of an article is divided into several stages, e.g., uncorrected preprint abstract, uncorrected preprint, corrected preprint, formal article, revised formal article.

5.5 Requirements for acceptance: First, if a manuscript written in English contains a title, at least an author representative, an abstract, and the statements required by Newpubli on ethics and copyright, it shall be accepted for publication as an uncorrected preprint abstract, or an uncorrected preprint if its full text has been submitted. Second, an uncorrected preprint shall be accepted as corrected preprint when Newpubli Editorial Team have found that it has met the following six criteria: the first or corresponding author has done research for no less than five years; the manuscript is well written in English; the manuscript is in the required format; the manuscript is mainly based on novel data, novel inferences, and/or novel views; the manuscript has met the ethical requirements of Newpubli; the manuscript has met the copyright requirements of Newpubli. Third, when the corrected preprint has obtained a value rank through peer review, it shall be accepted for formal publication as an article.

5.6 Solid peer review: the peer review process is uniquely divided into five stages in Newpubli. These five stages of peer review are useful to minimize the review burden of each reviewer, minimize prejudice of reviewers in selecting and rating articles, ensure the peer review quality, and disseminate the relevant novel research results among the most interested researchers.
5.6.1 The first stage of peer review is optional, and it is insensitive and only for providing detailed advice on manuscript revision by at least one expert invited by the authors. The invited experts can be the supervisor, classmates or friends of the authors. They should have much experience in the relevant field and English expression, and they can be properly rewarded by the author side in a rational way (e.g., through payment, some service or authorship). Although this stage of peer review is optional, it is very useful to improve the value of manuscripts, and so its significance should be well recognized by all authors, especially for those who are not good at scientific writing.
5.6.2 The second stage of peer review is also optional and only for examination in grammar and format. It is conducted by one editing company which is selected by the corresponding author from those having been accredited by Newpubli or another well-known editing company. The editing company will be paid by the corresponding authors. The editing companies do not have any financial relationships with us (Newpubli Corporation and Newpubli). This stage of peer review can further ensure that each article is well written.
5.6.3 The third stage of peer review is conducted by Newpubli Editorial Team after the optional second peer review, to judge whether the preprint is ready to be rated by outer peer review experts according to the six criteria mentioned above related to authorship, writing, format, novelty, ethics and copyright.
5.6.4 The fourth stage of peer review is sensitive and mainly for value rating, as set forth below, by experts invited by Newpubli Editorial Team. The ratings given by the peer reviewers are hidden in the online database and blind to everyone. This ensures that the rating is a type of secret ballot to minimize prejudice of the peer review. Many experts from different affiliations are invited by journal Newpubli Editorial Team to ensure at least five of them accept the invitation and provide the rating to further minimize prejudice of the peer review. The median of the ratings of the experts shall be calculated as the first value rank that is designated as the peer review rank (abbreviated as the PR-Rank) of the relevant preprint. The calculation is also useful to minimize prejudice of the peer review. The PR-Rank is calculated automatically by software and cannot be changed by anyone.
5.6.5 The fifth stage of peer review is done after an article has been formally published by Newpubli, and the peer review is given by any registered readers who want to make comments online on the article. Authors may be requested by Newpubli Editorial Team to respond to some of the comments.

5.7 Article value ranking: Newpubli uniquely provides four value ranks for each article published by the journal. When a preprint has passed the third stage of peer review as mentioned above, at least five experts invited by a Newpubli editor shall rate the manuscript to calculate the PR-Rank. A total of nine categories of PR-Ranks (1–9) are set in Newpubli, and articles whose PR-Ranks are 1, 2, 3, 4, 5, 6, 7, 8 and 9 are largely as valuable as those published in some journals whose IFs are 0–0.5, 0.5–1.5, 1.5–2.5, 2.5–3.5, 3.5–4.5, 4.5–5.5, 5.5–10.5, 10.5–20.5 and ≥20.5, respectively, as rated through the peer review. The median of the ratings of peer reviewers is calculated and taken as the PR-Rank of an article. The PR-Rank can rate the value of an article in a direct, fair, rapid and clear way. This is distinct from the post-publication metrics provided by the fourth generation of journals reflecting article value in a late, unclear and complicated way. Additionally, if an article published by Newpubli has been cited during the first one, two and five years after publication, for example, for 2, 5 and 12 times, respectively, then the second, third and fourth ranks of this article will be 2 (=2/1), 2.5 (=5/2) and 2.4 (=12/5), respectively. These three ranks can provide additional data for reflecting the value of an article. For example, if an article published by Newpubli is of a low PR-Rank, but its second, third and fourth ranks are all high, this indicates that the article is likely of high value and its PR-Rank is likely an underestimation. The second, third and fourth ranks are designated as the one-year rank (OY-Rank), the two-year rank (TY-Rank), and the five-year rank (FY-Rank), respectively.
5.8 Sub-journals of Newpubli: Newpubli uniquely has nine sub-journals which formally publish articles whose PR-Ranks are 1, 2, 3, 4, 5, 6, 7, 8 and 9, respectively, namely those articles which are rated through peer review to be largely as valuable as the ones published in some journals whose impact factors are 0–0.5, 0.5–1.5, 1.5–2.5, 2.5–3.5, 3.5–4.5, 4.5–5.5, 5.5–10.5, 10.5–20.5 and ≥20.5, respectively. We hope that Newpubli will appear in the Journal Citation Reports and receive its IF in the future. Moreover, the IF of each sub-journal of Newpubli shall be estimated using the standard method, so that articles published by each sub-journal of Newpubli can be rated not only by the article-based PR-Rank, OY-Rank, TY-Rank and FY-Rank, but also by the traditional method using IFs.
5.9 Requirements for publication acceptance: If we found that the abstract of your manuscript is well written, we can publish it as a preprint abstract soon after your submission, before you have completed its full text. If we found that the full text of your manuscript has been completed, we can publish it as a preprint soon after your submission. If we found that your preprint has met all the aforementioned six requirements as assessed through the second stage of peer review, and the third stage of peer review has completed or has not been chosen by you, we shall begin the fourth stage of peer review. We shall formally publish your manuscript after its PR-Rank has been calculated peer review. Newpubli may retract a published preprint abstract, preprint or article at any time if we found the preprint abstract, preprint or article has not met the requirements of Newpubli on ethics, copyright or authorship. Newpubli shall not reject a manuscript only because some reviewers commented that it is of limited value or technically unreliable, for multiple reasons: the comments may be wrong; the comments and the response of the authors to these comments shall be published along with the manuscript to aid readers to have their own judgment; a manuscript of limited value or technically unreliable can also provide some interesting novel research data for readers, and this is useful to solve the academia problem that useful information on many topics is deficient; a manuscript of limited value or technically unreliable shall likely be rated with a low value rank, which shall raise the vigilance of readers in judging the value and reliability of the manuscript. Moreover, readers can search, select and judge articles through their value ranks to avoid another academia problem that information on many other topics is too much or unreliable.
5.10 Comments of readers: Readers of Newpubli can make comments on each article published by Newpubli if they have been registered as users of Newpubli, and some of the comments shall be responded by authors and/or Newpubli Editorial Team.
5.11 Attribution of contributors: We will credit the contribution of all contributors of the journal. We will quantify and document the contribution of all authors, editors and readers of the journal as well as all the reviewers invited by Newpubli. Authors, readers and reviewers all have the opportunities to be awarded by Newpubli. Awarded authors and reviewers shall have the opportunities to be academic editors of the journal. Besides, the journal will also properly acknowledge donors who provide financial support for them through the worldwide and long-term impact of the journal.
5.12 Partially owned by researchers: 40% of all the original shares of Newpubli shall be bestowed to authors and reviewers in a rational way, so that they shall be the owners of Newpubli rather than the free servants of other academic journals. Please see here for more information.
5.13 Free open access publication: Newpubli Corporation is not for profit and of low cost partially due to active participation of authors in peer review and editing. Moreover, we believe that a good open access journal shall be able to obtain enough financial support by advertisement revenue, donation and government budget. Therefore, author need not pay ANY fee for open access publication. Although authors need not pay any fee for open access publication, they are requested to actively participate in the peer review of the journal. If any one is required through telephone, email or other ways to pay some money for open-access publication in Newpubli, the requirement should be fraud and sent from a cheat.
For more information, please see Editorial Policies of Newpubli.


6. Editors of Newpubli
6.1 Editor-in-Chief
Dr. Jiwang Chen, Department of Medicine, University of Illinois at Chicago, Chicago, USA
6.2 Inner Editors
Inner editors are responsible for checking the authorship, expression, format, novelty, ethics and copyright statement, inviting experts to conduct peer review, publishing articles, and managing the Newpubli website. Currently, we have the following inner editors:
Dr Changyun Ye, Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China
Dr Guofei Zhou, Department of Pediatrics, University of Illinois at Chicago, USA
Dr Jieyan Pan, Center for Advanced Retinal and Ophthalmic Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA
Dr Jiming Chen, Laboratory of Avian Disease Surveillance, China Animal Health and Epidemiology Center, China, Qingdao, China
Dr Jiwang Chen, Department of Medicine, University of Illinois at Chicago, Chicago, USA.
Dr Longshuang Huang, Department of Pharmacology, University of Illinois at Chicago, Chicago, USA
Mr Ligang Qian, Full-time Newpubli Editor
Miss Yanying Yuan, Full-time Newpubli Editor

6.3 Academic Editors

Academic Editors (AEs) of Newpubli are responsible to be active as authors, reviewers, readers, advisors and publicists of Newpubli. Currently, we have the following Academic Editors:

Dr Bin Wei, State Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, China

Dr Changyun Ye, Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China

Dr Chunying Li, Department of Biochemistry and Molecular Biology, Wayne State University, USA

Dr Daxin Peng, Key Laboratory of Animal Infectious Diseases, Yangzhou University, Yangzhou, China
Dr Dayan Wang, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China

Dr Fuping Zhang, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China

Dr Guofei Zhou, Department of Pediatrics, University of Illinois at Chicago, Chicago, USA
Dr Guoqing Pan, State Key Laboratory of Silkworm Genome Biology, Southwest University, Chongqing, China
Dr Haiyang Tang, Department of Medicine, University of Arizona, Tucson, USA

Dr Honglin Xu, The First Research Unit, National Vaccine & Serum Institute, Beijing, China

Dr Hongxuan He, National Research Center for Wildlife Born Diseases, Institute of Zoology, Chinese Academy of Sciences, Beijing, China
Dr Houhui Song, College of Animal Science and Technology, Zhejiang A&F University, Lin'an, China

Dr Jiaqiang Huang, School of Science, Beijing Jiaotong University, Beijing, China

Dr Jieqing Zhu, Blood Research Institute, BloodCenter of Wisconsin, Milwaukee, USA

Dr Jieyan Pan, Center for Advanced Retinal and Ophthalmic Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA

Dr Jiming Chen, Laboratory of Avian Disease Surveillance, China Animal Health and Epidemiology Center, China, Qingdao, China
Dr Jiangning Yang, Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden
Dr Jinsheng He, School of Science, Beijing Jiaotong University, Beijing, China

Dr Jiwang Chen, Department of Medicine, University of Illinois at Chicago, Chicago, USA

Dr Justin Jang Hann Chu, Department of Microbiology and Immunology, National University of Singapore, Singapore

Dr Koon Chu Yaiw, Department of Medicine, Karolinska Institutet, Stockholm, Sweden

Dr Longshuang Huang, Department of Pharmacology, University of Illinois at Chicago, Chicago, USA

Dr Peng Xu, CAFS Key Laboratory of Aquatic Genomics and Beijing Key Laboratory of Fishery Biotechnology, Centre for Applied Aquatic Genomics, Chinese Academy of Fishery Sciences, Beijing, China

Dr Ruanbao Zhou, Department of Biochemistry and Molecular Biology, Michigan State University, East Lansing, Michigan, USA

Dr Taimur A. Abbasi, Internal Medicine, Mercy Hospital & health Center, Chicago, USA

Dr Xiaojian Wang, State Key Laboratory of Cardiovascular Disease, FuWai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

Dr Xiaomin Wu, College of Medicine, the University of Arizona, Tucson, USA
Dr Xinkun Wang, Department of Biochemistry and Molecular Genetics, Northwestern University Feinberg School of Medicine, Chicago, USA
Dr Xiuguo Hua, Shanghai Key Laboratory of Veterinary Biotechnology, School of Agriculture and Biology, Shanghai Jiao Tong University, Shanghai, China
Dr Xiuqin Ni, Department of Pathology, Harbin Medical University (Daqing), Daqing, China

Dr Yihui Xu, Institute of Biophysics, Chinese Academy of Science, Beijing, China

Dr Yingxiong Qiu, College of Life Sciences, Zhejiang University, Hangzhou, China

Dr Yun-Ju Lee, Department of Physical Therapy, University of Illinois at Chicago, Chicago, USA

Dr Zhaojun Duan, National Insitute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China

Dr Zhiyu Dai, Department of Pharmacology, University of Illinois at Chicago, Chicago, USA
Dr Zhong Chen, Key Laboratory of Tropical Medicinal Plant Chemistry of Ministry of Education, Hainan Normal University, Haikou, China
Dr Zhongwen Xie, Department of Physiology, College of Medicine, University of Kentucky, Lexington, USA


7. Contact us

For your relationships with us, please see Terms of Use.

For editorial policies of Newpubli, please see Editorial Policies.

For preparing and submitting manuscripts, please see Author Guide.

For providing peer reviews, please see Reviewer Guide.

For providing comments, please see Reader Guide. For responsibilities of academic editors, please see Newpubli Editors.

For information about Newpubli Express which is also published by Newpubli Corporation, please see Newpubli Express. For accreditation of editing company, please see Editing Company Guide.

For answers to some Frequently Asked Questions, please see FAQs.

For more information about us, please send emails to journal@newpubli.com.


Last update: 18-02-2016


© 2016 Newpubli Corporation.


Terms of Use| Privacy Statement| Advertise| Contact us

© Newpubli Corporation unless otherwise stated